CN100340575C - 人源化抗ErbB2抗体及其在制备药物中的应用 - Google Patents
人源化抗ErbB2抗体及其在制备药物中的应用 Download PDFInfo
- Publication number
- CN100340575C CN100340575C CNB008118981A CN00811898A CN100340575C CN 100340575 C CN100340575 C CN 100340575C CN B008118981 A CNB008118981 A CN B008118981A CN 00811898 A CN00811898 A CN 00811898A CN 100340575 C CN100340575 C CN 100340575C
- Authority
- CN
- China
- Prior art keywords
- antibody
- cell
- cancer
- erbb
- erbb2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Packages (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14131699P | 1999-06-25 | 1999-06-25 | |
US60/141,316 | 1999-06-25 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007101411129A Division CN101121021B (zh) | 1999-06-25 | 2000-06-23 | 人源化抗ErbB2抗体及用抗ErbB2抗体进行的治疗 |
CNA2007101411114A Division CN101121750A (zh) | 1999-06-25 | 2000-06-23 | 人源化抗ErbB2抗体及用抗ErbB2抗体进行的治疗 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1370082A CN1370082A (zh) | 2002-09-18 |
CN100340575C true CN100340575C (zh) | 2007-10-03 |
Family
ID=22495168
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2007101411114A Pending CN101121750A (zh) | 1999-06-25 | 2000-06-23 | 人源化抗ErbB2抗体及用抗ErbB2抗体进行的治疗 |
CNB008118981A Expired - Lifetime CN100340575C (zh) | 1999-06-25 | 2000-06-23 | 人源化抗ErbB2抗体及其在制备药物中的应用 |
CN200910126199.1A Expired - Lifetime CN101518653B (zh) | 1999-06-25 | 2000-06-23 | 使用抗ErbB抗体-类美坦素偶联物的治疗方法 |
CN2007101411129A Expired - Lifetime CN101121021B (zh) | 1999-06-25 | 2000-06-23 | 人源化抗ErbB2抗体及用抗ErbB2抗体进行的治疗 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2007101411114A Pending CN101121750A (zh) | 1999-06-25 | 2000-06-23 | 人源化抗ErbB2抗体及用抗ErbB2抗体进行的治疗 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200910126199.1A Expired - Lifetime CN101518653B (zh) | 1999-06-25 | 2000-06-23 | 使用抗ErbB抗体-类美坦素偶联物的治疗方法 |
CN2007101411129A Expired - Lifetime CN101121021B (zh) | 1999-06-25 | 2000-06-23 | 人源化抗ErbB2抗体及用抗ErbB2抗体进行的治疗 |
Country Status (33)
Families Citing this family (226)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8038994B2 (en) | 1996-05-15 | 2011-10-18 | Quest Pharmatech Inc. | Combination therapy for treating disease |
WO2003034977A2 (en) * | 2001-10-26 | 2003-05-01 | Altarex Medical Corp. | Combination therapy for treating disease |
MXPA01013240A (es) * | 1999-06-25 | 2002-06-21 | Genentech Inc | Metodo de tratamiento utilizando conjugados de anticuerpo contra erbb-maytansionoide. |
SI1189641T1 (sl) * | 1999-06-25 | 2009-12-31 | Genentech Inc | Humanizirana protitelesa proti ErbB2 in zdravljenje s protitelesi proti ErbB2 |
US6825333B1 (en) | 1999-08-20 | 2004-11-30 | Chiron Corporation | EGFH2 genes and gene products |
US6627196B1 (en) | 1999-08-27 | 2003-09-30 | Genentech, Inc. | Dosages for treatment with anti-ErbB2 antibodies |
AU775373B2 (en) | 1999-10-01 | 2004-07-29 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
KR101135233B1 (ko) | 2000-05-19 | 2012-04-12 | 제넨테크, 인크. | ErbB 길항제에 의한 암 치료요법에 대한 효과적인 반응의 가능성을 개선시키기 위한 유전자 검출 분석 |
EP1228766A1 (en) * | 2001-01-31 | 2002-08-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | PYK2 phosphorylation by HER3 induces tumor invasion |
WO2003087338A2 (en) * | 2002-04-11 | 2003-10-23 | Amgen, Inc. | Her-2 receptor tyrosine kinase molecules and uses thereof |
ITTO20020340A1 (it) * | 2002-04-19 | 2003-10-20 | Biother Di Contardi Gabriella | Localizzazione del recettore her2 mediante anticorpo umanizzato biotinilato. |
AU2003237367A1 (en) | 2002-06-03 | 2003-12-19 | Chiron Corporation | Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer |
AT413486B (de) | 2002-07-03 | 2006-03-15 | Igeneon Krebs Immuntherapie | Verwendung eines antikörpers gerichtet gegen lewis-antigene |
NO340576B1 (no) * | 2002-07-11 | 2017-05-15 | Hoffmann La Roche | Rekombinant, humanisert antistoff 2C4 (rhuMab 2C4) for anvendelse sammen med et andre, forskjellig vekstinhiberende anti-ErbB2-antistoff i en fremgangsmåte for behandling av kreft i en pasient og anvendelse derav for fremstilling av et medikament |
PT2263691E (pt) * | 2002-07-15 | 2012-11-12 | Hoffmann La Roche | Tratamento de cancro com o anticorpo anti-erbb2 monoclonal humanizado recombinante 2c4 (rhumab 2c4) |
SI1530482T1 (sl) | 2002-07-18 | 2014-03-31 | Helix Biopharma Corp. | Uporaba ureaze za inhibiranje rasti rakavih celic |
PT2314629E (pt) | 2002-07-18 | 2014-01-22 | Merus B V | Produção recombinante de misturas de anticorpos |
USRE47770E1 (en) | 2002-07-18 | 2019-12-17 | Merus N.V. | Recombinant production of mixtures of antibodies |
US7264800B2 (en) | 2002-07-18 | 2007-09-04 | Helix Biopharma Corporation | Method and composition for inhibiting cancer cell growth |
JP5138867B2 (ja) * | 2002-08-01 | 2013-02-06 | イミューノメディクス、インコーポレイテッド | α−フェトタンパク質Immu31抗体および融合タンパク質ならびにその使用方法 |
US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
KR20050065587A (ko) * | 2002-10-08 | 2005-06-29 | 이뮤노메딕스, 인코오포레이티드 | 항체 치료법 |
CA2508831C (en) | 2002-12-13 | 2012-05-01 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
JP2007517767A (ja) * | 2003-03-11 | 2007-07-05 | ダナ ファーバー キャンサー インスティテュート | ウイルスの病原性の阻害方法 |
ES2368737T3 (es) * | 2003-04-23 | 2011-11-21 | Medarex, Inc. | Anticuerpos humanizados contra el receptor de interferon alfa 1 (ifnar-1). |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
AT500651B9 (de) * | 2003-05-27 | 2010-04-15 | Altropus Gmbh | Aktiv immunisierender antikörper |
US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
ES2408582T3 (es) | 2003-05-30 | 2013-06-21 | Merus B.V. | Biblioteca de Fab para la preparación de una mezcla de anticuerpos |
DK3095793T3 (da) | 2003-07-28 | 2020-05-25 | Genentech Inc | Reducering af udvaskning af protein A under en protein A-affinitetskromatografi |
WO2005020923A2 (en) * | 2003-08-29 | 2005-03-10 | Cedars-Sinai Medical Center | Composition and method for the treatment of cancer and other physiologic conditions based on modulation of the ppar-gamma pathway and her-kinase axis |
JP4621674B2 (ja) * | 2003-09-18 | 2011-01-26 | レイベン バイオテクノロジーズ,インコーポレイティド | Kid3およびkid3に結合するkid3抗体 |
CA2547435A1 (en) * | 2003-11-28 | 2005-06-09 | Mitra Medical Ab | Targeting of erb antigens |
EP2286844A3 (en) * | 2004-06-01 | 2012-08-22 | Genentech, Inc. | Antibody-drug conjugates and methods |
SV2006002143A (es) * | 2004-06-16 | 2006-01-26 | Genentech Inc | Uso de un anticuerpo para el tratamiento del cancer resistente al platino |
JP2008507520A (ja) | 2004-07-22 | 2008-03-13 | ジェネンテック・インコーポレーテッド | Her2抗体組成物 |
US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
WO2006034488A2 (en) | 2004-09-23 | 2006-03-30 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
CA2587519A1 (en) * | 2004-12-07 | 2006-06-15 | Genentech, Inc. | Selecting patients for therapy with a her inhibitor |
TWI441646B (zh) * | 2005-01-21 | 2014-06-21 | Genentech Inc | 帕妥珠單抗(pertuzumab)用於製備治療人類病患癌症之藥物的用途 |
ES2440481T3 (es) | 2005-02-23 | 2014-01-29 | Genentech, Inc. | Prolongación del tiempo hasta la progresión de la enfermedad o supervivencia en pacientes de cáncer de ovario usando pertuzumab |
AR053272A1 (es) * | 2005-05-11 | 2007-04-25 | Hoffmann La Roche | Determinacion de responsivos a la quimioterapia |
US7858843B2 (en) | 2005-06-06 | 2010-12-28 | Genentech, Inc. | Gene disruptions, compositions and methods relating thereto |
US7700299B2 (en) | 2005-08-12 | 2010-04-20 | Hoffmann-La Roche Inc. | Method for predicting the response to a treatment |
AU2006280321A1 (en) | 2005-08-15 | 2007-02-22 | Genentech, Inc. | Gene disruptions, compositions and methods relating thereto |
KR101164820B1 (ko) | 2005-09-22 | 2012-07-12 | 삼성전자주식회사 | 디스플레이장치 |
US8080534B2 (en) | 2005-10-14 | 2011-12-20 | Phigenix, Inc | Targeting PAX2 for the treatment of breast cancer |
AU2006335053A1 (en) | 2005-11-21 | 2007-07-19 | Genentech, Inc. | Novel gene disruptions, compositions and methods relating thereto |
AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
EP2050335A1 (en) | 2006-02-17 | 2009-04-22 | Genentech, Inc. | Gene disruptions, compositions and methods relating thereto |
TW200812615A (en) | 2006-03-22 | 2008-03-16 | Hoffmann La Roche | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 |
AR060358A1 (es) | 2006-04-06 | 2008-06-11 | Novartis Vaccines & Diagnostic | Quinazolinas para la inhibicion de pdk 1 |
EP2082645A1 (en) | 2006-04-19 | 2009-07-29 | Genentech, Inc. | Novel gene disruptions, compositions and methods relating thereto |
MX2008015132A (es) | 2006-05-30 | 2008-12-10 | Genentech Inc | Anticuerpos e inmunoconjugados y sus usos. |
CA2654584A1 (en) * | 2006-06-05 | 2007-12-21 | Genentech, Inc. | Extending survival of cancer patients with elevated levels of egf or tgf-alpha |
DK2056874T3 (da) | 2006-08-21 | 2012-10-15 | Hoffmann La Roche | Tumorterapi med et anti-vegf-antistof |
WO2008031531A1 (en) * | 2006-09-15 | 2008-03-20 | F. Hoffmann-La Roche Ag | Tumor therapy with a combination of anti-her2 antibodies |
NZ576855A (en) * | 2006-10-12 | 2012-08-31 | Forerunner Pharma Res Co Ltd | Diagnosis and treatment of cancer using anti-ereg antibody |
EP2061814B1 (en) | 2006-10-27 | 2012-06-06 | Genentech, Inc. | Antibodies and immunoconjugates and uses therefor |
WO2008109440A2 (en) | 2007-03-02 | 2008-09-12 | Genentech, Inc. | Predicting response to a her dimerisation inhibitor based on low her3 expression |
US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
ES2417148T3 (es) | 2007-06-08 | 2013-08-06 | Genentech, Inc. | Marcadores de expresión génica de la resistencia tumoral al tratamiento con inhibidor de HER2 |
CN101918844A (zh) * | 2007-06-18 | 2010-12-15 | 米迪缪尼有限公司 | 表达epha2和erbb2的细胞的协同治疗 |
WO2009012256A1 (en) | 2007-07-16 | 2009-01-22 | Genentech, Inc. | Humanized anti-cd79b antibodies and immunoconjugates and methods of use |
DK2474557T3 (da) | 2007-07-16 | 2014-11-10 | Genentech Inc | Anti-CD79b-antistoffer og immunkonjugater og fremgangsmåder til anvendelse |
RU2498991C2 (ru) | 2007-10-30 | 2013-11-20 | Дженентек, Инк. | Очистка антител с помощью катионообменной хроматографии |
AU2008328781A1 (en) | 2007-11-27 | 2009-06-04 | Ablynx N.V. | Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same |
PA8809001A1 (es) | 2007-12-20 | 2009-07-23 | Novartis Ag | Compuestos organicos |
PE20091174A1 (es) * | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
US8557242B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | ERBB2 antibodies comprising modular recognition domains |
US8574577B2 (en) | 2008-01-03 | 2013-11-05 | The Scripps Research Institute | VEGF antibodies comprising modular recognition domains |
US8557243B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | EFGR antibodies comprising modular recognition domains |
US8454960B2 (en) | 2008-01-03 | 2013-06-04 | The Scripps Research Institute | Multispecific antibody targeting and multivalency through modular recognition domains |
NZ586701A (en) | 2008-01-03 | 2013-07-26 | Scripps Research Inst | Antibody targeting through a modular recognition domain (MRD) wherein the MRD targets angiopoietin-2 (ANG-2) |
TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至her2結構域ii之抗體及其酸性變異體的組合物 |
DK2657253T3 (en) | 2008-01-31 | 2017-10-09 | Genentech Inc | Anti-CD79b antibodies and immune conjugates and methods of use |
DK2260111T3 (en) | 2008-03-14 | 2015-09-14 | Genentech Inc | Genetic variations that are associated with drug resistance |
EP2644204B1 (en) * | 2008-03-18 | 2017-04-19 | Genentech, Inc. | Combinations of an Anti-HER2 antibody-drug conjugate and pertuzumab |
EP2294178B1 (en) | 2008-05-23 | 2014-07-16 | Siwa Corporation | Methods for facilitating regeneration |
BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
EP2684570A1 (en) | 2008-09-10 | 2014-01-15 | F. Hoffmann-La Roche AG | Compositions and methods for the prevention of oxidative degradation of proteins |
CN102448494B (zh) | 2009-02-13 | 2016-02-03 | 免疫医疗公司 | 具有胞内可裂解的键的免疫共轭物 |
CN104447995A (zh) | 2009-03-20 | 2015-03-25 | 霍夫曼-拉罗奇有限公司 | 双特异性抗-her抗体 |
US8466260B2 (en) | 2009-04-01 | 2013-06-18 | Genentech, Inc. | Anti-FcRH5 antibodies and immunoconjugates and methods of use |
CN102361883A (zh) | 2009-04-07 | 2012-02-22 | 罗氏格黎卡特股份公司 | 双特异性抗-ErbB-1/抗-c-Met抗体 |
JP5808052B2 (ja) | 2009-05-29 | 2015-11-10 | 中外製薬株式会社 | Egfファミリーリガンドのアンタゴニストを成分とする医薬組成物 |
EP2435071A1 (en) | 2009-05-29 | 2012-04-04 | F. Hoffmann-La Roche AG | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
US8293753B2 (en) | 2009-07-02 | 2012-10-23 | Novartis Ag | Substituted 2-carboxamide cycloamino ureas |
US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
SG10201901417UA (en) | 2009-08-11 | 2019-03-28 | Genentech Inc | Production of proteins in glutamine-free cell culture media |
BR112012003346A2 (pt) * | 2009-08-15 | 2016-11-16 | Genentech Inc | metodo de tratamento de um paciente diagnostico com cancer de mama metastico previamente tratado kit para tratamento de cancer de mama metastatico previamente tratado em um paciente humano metodo para instruir um paciente humano com cancer metodo promocional e metodo comercial |
KR101764449B1 (ko) | 2009-09-01 | 2017-08-02 | 제넨테크, 인크. | 변형된 단백질 a 용리를 통한 증진된 단백질 정제 |
AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
SI2486141T1 (en) | 2009-10-07 | 2018-06-29 | Macrogenics, Inc. | FC REGION-CONTAINING POLYPETHYDE, AFFECTING A BETTERED EFFECTORAL FUNCTION, BY CHANGES IN THE SCOPE OF FUKOZILATION AND METHODS FOR THEIR USE |
US8658175B2 (en) * | 2009-10-28 | 2014-02-25 | Abbvie Biotherapeutics Inc. | Anti-EGFR antibodies and their uses |
BR112012010153B1 (pt) | 2009-11-05 | 2022-05-03 | Genentech, Inc | Método de produção de um anticorpo |
CN102812045B (zh) | 2009-11-13 | 2018-04-13 | 第一三共欧洲有限公司 | 用于治疗或预防人表皮生长因子受体‑3(her‑3)相关疾病的材料和方法 |
BR112012012983A2 (pt) | 2009-12-04 | 2020-09-15 | Genentech Inc | método para sintetizar um anticorpo multiespecífico, método para sintetizar um painel de anticorpos multiespecíficos, método para sintetizar um análogo de anticorpo, método para sintetizar um painel de análogos de anticorpo e composições |
JP5742714B2 (ja) * | 2010-02-04 | 2015-07-01 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
CN102892779B (zh) | 2010-02-18 | 2016-12-21 | 基因泰克公司 | 神经调节蛋白拮抗剂及其在治疗癌症中的用途 |
US8609095B2 (en) | 2010-03-04 | 2013-12-17 | Symphogen A/S | Anti-HER2 antibodies and compositions |
CA2792125C (en) | 2010-03-22 | 2019-02-12 | Genentech, Inc. | Compositions and methods useful for stabilizing protein-containing formulations |
MX2012012743A (es) | 2010-05-03 | 2012-11-23 | Genentech Inc | Composiciones y metodos utiles para reducir la viscosidad de formulaciones que contienen proteina. |
WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
EP2575880B1 (en) | 2010-05-27 | 2019-01-16 | Genmab A/S | Monoclonal antibodies against her2 epitope |
EP3539988A3 (en) | 2010-05-27 | 2019-12-04 | Genmab A/S | Monoclonal antibodies against her2 |
RU2614125C2 (ru) | 2010-05-28 | 2017-03-22 | Дженентек, Инк. | Снижение уровня лактата и увеличение продукции полипептида путем ингибирования экспрессии лактатдегидрогеназы и киназы пируватдегидрогеназы |
MX336109B (es) | 2010-06-03 | 2016-01-08 | Genentech Inc | Formacion de imagenes inmuno-tep de anticuerpos e inmunoconjugados y usos de lo mismo. |
EP2579897A1 (en) | 2010-06-08 | 2013-04-17 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
SG186783A1 (en) | 2010-06-24 | 2013-02-28 | Genentech Inc | Compositions and methods containing alkylgycosides for stabilizing protein- containing formulations |
US20120100166A1 (en) | 2010-07-15 | 2012-04-26 | Zyngenia, Inc. | Ang-2 Binding Complexes and Uses Thereof |
AR082418A1 (es) | 2010-08-02 | 2012-12-05 | Novartis Ag | Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico |
TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
US8721571B2 (en) | 2010-11-22 | 2014-05-13 | Siwa Corporation | Selective removal of cells having accumulated agents |
EP2643353A1 (en) | 2010-11-24 | 2013-10-02 | Novartis AG | Multispecific molecules |
WO2012084829A1 (en) | 2010-12-21 | 2012-06-28 | F. Hoffmann-La Roche Ag | Isoform enriched antibody preparation and method for obtaining it |
WO2012085111A1 (en) | 2010-12-23 | 2012-06-28 | F. Hoffmann-La Roche Ag | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
EP2655414B1 (en) | 2010-12-23 | 2018-08-29 | Roche Diagniostics GmbH | Bispecific binding agent |
PE20140293A1 (es) | 2011-01-31 | 2014-03-19 | Novartis Ag | Novedosos derivados heterociclicos |
WO2012122378A2 (en) * | 2011-03-08 | 2012-09-13 | The Trustees Of The University Of Pennsylvania | Antibody-like proteins for therapeutic and diagnostic use |
AU2012245116A1 (en) | 2011-04-20 | 2013-11-07 | Genmab A/S | Bispecific antibodies against HER2 and CD3 |
CN106432506A (zh) | 2011-05-24 | 2017-02-22 | 泽恩格尼亚股份有限公司 | 多价和单价多特异性复合物及其用途 |
BR112014003431A2 (pt) | 2011-08-17 | 2017-06-13 | Genentech Inc | anticorpo, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, agente farmacêutico, uso do anticorpo, método de tratamento de um indivíduo que tem câncer e método de aumento de tempo para recorrência de tumor |
CN104334189A (zh) | 2011-10-14 | 2015-02-04 | 霍夫曼-拉罗奇有限公司 | Her2二聚化抑制剂帕妥珠单抗的用途和包含her2二聚化抑制剂帕妥珠单抗的制品 |
WO2013063229A1 (en) | 2011-10-25 | 2013-05-02 | The Regents Of The University Of Michigan | Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells |
EP2771342B1 (en) | 2011-10-28 | 2016-05-18 | Novartis AG | Purine derivatives and their use in the treatment of disease |
BR112014012539B1 (pt) | 2011-11-23 | 2022-12-20 | Medimmune, Llc | Anticorpo que se liga especificamente a her3, composição compreendendo o mesmo, e usos do anticorpo |
AU2012346540C1 (en) | 2011-11-30 | 2019-07-04 | Genentech, Inc. | ErbB3 mutations in cancer |
EP2788500A1 (en) | 2011-12-09 | 2014-10-15 | F.Hoffmann-La Roche Ag | Identification of non-responders to her2 inhibitors |
TR201815709T4 (tr) | 2011-12-22 | 2018-11-21 | Hoffmann La Roche | İyon değişim membranı kromatografisi. |
TWI593705B (zh) | 2011-12-28 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient |
AU2013214254B2 (en) | 2012-01-31 | 2016-04-21 | Novartis Ag | Method of treating cancer |
EP2638916A1 (en) | 2012-03-16 | 2013-09-18 | Covagen AG | Novel binding molecules with antitumoral activity |
JP2015514710A (ja) | 2012-03-27 | 2015-05-21 | ジェネンテック, インコーポレイテッド | Her3阻害剤に関する診断及び治療 |
NZ772318A (en) | 2012-04-20 | 2023-06-30 | Merus Nv | Methods and means for the production of ig-like molecules |
KR101505157B1 (ko) | 2012-05-08 | 2015-03-24 | 주식회사 종근당 | 항―ErbB2 항체 변이체 |
AU2013263043B2 (en) | 2012-05-16 | 2016-06-16 | Novartis Ag | Dosage regimen for a PI-3 kinase inhibitor |
CA2889298C (en) | 2012-11-30 | 2024-01-02 | Anton Belousov | Identification of patients in need of pd-l1 inhibitor cotherapy |
US20150329524A1 (en) | 2013-01-10 | 2015-11-19 | Glaxosmithkline Intellectual Property (No.2) Limited | Fatty acid synthase inhibitors |
AR094403A1 (es) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
EA201890895A1 (ru) | 2013-03-15 | 2019-02-28 | Зинджения, Инк. | Мультивалентные и моновалентные мультиспецифические комплексы и их применение |
CN104628846B (zh) | 2013-11-06 | 2019-12-06 | 三生国健药业(上海)股份有限公司 | 重组蛋白质的纯化方法 |
HUE055269T2 (hu) * | 2013-11-19 | 2021-11-29 | Remegen Co Ltd | Anti-HER2 ellenanyag és konjugátum |
AU2014357292B2 (en) * | 2013-11-27 | 2020-06-25 | Zymeworks Bc Inc. | Bispecific antigen-binding constructs targeting HER2 |
TN2016000179A1 (en) | 2013-12-06 | 2017-10-06 | Novartis Ag | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor. |
SG11201603960XA (en) | 2014-01-31 | 2016-07-28 | Daiichi Sankyo Co Ltd | Anti-her2 antibody-drug conjugate |
US20160361309A1 (en) | 2014-02-26 | 2016-12-15 | Glaxosmithkline Intellectual Property (No.2) Limited | Methods of treating cancer patients responding to ezh2 inhibitor gsk126 |
CA2941687A1 (en) | 2014-03-14 | 2015-09-17 | Genentech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
JP2017512765A (ja) | 2014-04-11 | 2017-05-25 | メディミューン,エルエルシー | 二重特異性her2抗体 |
AR101844A1 (es) | 2014-09-12 | 2017-01-18 | Genentech Inc | Anticuerpos y conjugados modificados genéticamente con cisteína |
US10385380B2 (en) | 2014-10-02 | 2019-08-20 | The Regents Of The University Of California | Personalized protease assay to measure protease activity in neoplasms |
US9993535B2 (en) | 2014-12-18 | 2018-06-12 | Siwa Corporation | Method and composition for treating sarcopenia |
US10358502B2 (en) | 2014-12-18 | 2019-07-23 | Siwa Corporation | Product and method for treating sarcopenia |
MA41414A (fr) | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
KR101515535B1 (ko) | 2015-01-28 | 2015-05-06 | 주식회사 종근당 | 항―ErbB2 항체 변이체 |
AU2016262168B2 (en) * | 2015-05-13 | 2022-06-23 | Zymeworks Bc Inc. | Antigen-binding constructs targeting HER2 |
WO2017025871A1 (en) | 2015-08-07 | 2017-02-16 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy comprising anti ctla-4 antibodies |
CA3000815C (en) * | 2015-10-13 | 2022-11-01 | Siwa Corporation | Anti-age antibodies and methods of use thereof |
RU2018119085A (ru) | 2015-11-02 | 2019-12-04 | Новартис Аг | Схема введения ингибитора фосфатидилинозитол-3-киназы |
CN106729743B (zh) | 2015-11-23 | 2021-09-21 | 四川科伦博泰生物医药股份有限公司 | 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用 |
US20190256608A1 (en) | 2015-12-01 | 2019-08-22 | Glaxosmithkline Intellectual Property Development Limited | Combination treatments and uses and methods thereof |
BR112018011781A2 (pt) | 2015-12-14 | 2018-12-04 | Macrogenics Inc | molécula biespecífica possuindo um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de pd-1 e um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de ctla-4, e composição farmacêutica |
CN105646704B (zh) * | 2015-12-28 | 2019-11-15 | 广西医科大学 | 抗p185erbB2人鼠嵌合抗体ChAb26、乳腺特异性表达载体、转基因FVB小鼠及其制备方法 |
WO2017143073A1 (en) | 2016-02-19 | 2017-08-24 | Siwa Corporation | Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (age) |
KR20180119570A (ko) * | 2016-03-15 | 2018-11-02 | 메리맥 파마슈티컬즈, 인크. | 항-ErbB3 항체를 포함하는 병용 요법을 이용한 ER+, HER2-, HRG+ 유방암의 치료 |
KR20180133452A (ko) | 2016-04-15 | 2018-12-14 | 시와 코퍼레이션 | 신경퇴행성 질환을 치료하기 위한 항-노화 항체 |
US20190151346A1 (en) | 2016-05-10 | 2019-05-23 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Combinations therapies for the treatment of cancer |
EP3455260B1 (en) * | 2016-05-12 | 2022-07-06 | Agency for Science, Technology and Research | Anti-erbb-2 antibodies and uses thereof |
WO2017222535A1 (en) | 2016-06-23 | 2017-12-28 | Siwa Corporation | Vaccines for use in treating various diseases and disorders |
WO2018060833A1 (en) | 2016-09-27 | 2018-04-05 | Novartis Ag | Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib |
SG10201912173RA (en) | 2016-10-07 | 2020-02-27 | Daiichi Sankyo Co Ltd | Therapy for drug-resistant cancer by administration of anti-her2 antibody/drug conjugate |
EP3552626A4 (en) | 2016-12-12 | 2020-06-10 | Daiichi Sankyo Company, Limited | ASSOCIATION OF AN ANTIBODY DRUG CONJUGATE AND AN IMMUNE CONTROL POINT INHIBITOR |
US10995151B1 (en) | 2017-01-06 | 2021-05-04 | Siwa Corporation | Methods and compositions for treating disease-related cachexia |
US10858449B1 (en) | 2017-01-06 | 2020-12-08 | Siwa Corporation | Methods and compositions for treating osteoarthritis |
US10961321B1 (en) | 2017-01-06 | 2021-03-30 | Siwa Corporation | Methods and compositions for treating pain associated with inflammation |
WO2018127791A2 (en) * | 2017-01-06 | 2018-07-12 | Biosion, Inc. | Erbb2 antibodies and uses therefore |
US10925937B1 (en) | 2017-01-06 | 2021-02-23 | Siwa Corporation | Vaccines for use in treating juvenile disorders associated with inflammation |
EP4389226A2 (en) | 2017-02-24 | 2024-06-26 | MacroGenics, Inc. | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof |
EP3589286B1 (en) | 2017-03-02 | 2022-08-03 | ASLAN Pharmaceuticals Pte Ltd | Dhodh inhibitor for treating haematological cancer |
US11077189B2 (en) | 2017-03-02 | 2021-08-03 | Genentech Inc. | Adjuvant treatment of HER2-positive breast cancer |
CN110612124B (zh) | 2017-03-22 | 2024-04-16 | 豪夫迈·罗氏有限公司 | 用于治疗眼部病症的优化的抗体组合物 |
EP3609923A1 (en) | 2017-04-13 | 2020-02-19 | Siwa Corporation | Humanized monoclonal advanced glycation end-product antibody |
WO2018222135A1 (en) | 2017-06-02 | 2018-12-06 | Aslan Pharmaceuticals Pte Ltd | Cancer therapy |
CN107417791B (zh) * | 2017-08-17 | 2020-09-22 | 合肥瀚科迈博生物技术有限公司 | 抗人ErbB2双特异性抗体、其制备方法及用途 |
CA3073383C (en) | 2017-08-23 | 2023-10-31 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate preparation and lyophilization for same |
EP3677589A4 (en) | 2017-08-31 | 2021-04-21 | Daiichi Sankyo Company, Limited | IMPROVED PROCESS FOR PREPARING ANTIBODY-ACTIVE CONJUGATE |
CN117838880A (zh) | 2017-08-31 | 2024-04-09 | 第一三共株式会社 | 制备抗体-药物缀合物的新方法 |
CN107789631B (zh) * | 2017-11-03 | 2021-03-16 | 合肥瀚科迈博生物技术有限公司 | 抗人ErbB2双表位抗体-药物偶联物及其应用 |
KR20200098590A (ko) | 2017-12-12 | 2020-08-20 | 마크로제닉스, 인크. | 이중특이적 cd16-결합 분자 및 질환 치료에서의 그것의 용도 |
US11518801B1 (en) | 2017-12-22 | 2022-12-06 | Siwa Corporation | Methods and compositions for treating diabetes and diabetic complications |
BR112020016485A2 (pt) | 2018-02-15 | 2020-12-15 | Macrogenics, Inc. | Molécula de ligação, composição farmacêutica e método para o tratamento de uma doença |
EP3560945A1 (en) | 2018-04-27 | 2019-10-30 | F. Hoffmann-La Roche AG | Methods for purification of polypeptides using polysorbates |
CN112153989A (zh) | 2018-05-28 | 2020-12-29 | 第一三共株式会社 | 通过施用抗her2抗体-药物缀合物治疗her2突变的癌 |
AU2019309913A1 (en) | 2018-07-23 | 2021-03-11 | Trevi Therapeutics, Inc. | Treatment of chronic cough, breathlessness and dyspnea |
EP3828206A4 (en) | 2018-07-25 | 2022-04-20 | Daiichi Sankyo Company, Limited | METHOD OF PREPARING AN ANTIBODY DRUG CONJUGATE |
EP3831853A4 (en) | 2018-07-27 | 2022-06-01 | Daiichi Sankyo Company, Limited | ANTIBODY-DRUG CONJUGATE PROTEIN-RECOGNIZING DRUG UNIT |
TWI822822B (zh) | 2018-07-31 | 2023-11-21 | 日商第一三共股份有限公司 | 抗體-藥物結合物之用途 |
US20210290775A1 (en) | 2018-08-06 | 2021-09-23 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and tubulin inhibitor |
CN112739826A (zh) | 2018-08-23 | 2021-04-30 | 第一三共株式会社 | 抗体-药物缀合物的敏感性标志物 |
BR112021005634A2 (pt) | 2018-09-25 | 2021-06-29 | Absci, Llc | métodos de purificação de proteína |
WO2020084503A1 (en) | 2018-10-26 | 2020-04-30 | Cadila Healthcare Limited | A composition comprising antibody with reduced level of basic variants thereof |
CN113271942A (zh) | 2018-12-11 | 2021-08-17 | 第一三共株式会社 | 抗体-药物缀合物与parp抑制剂的组合 |
JPWO2020130125A1 (ja) | 2018-12-21 | 2021-11-04 | 第一三共株式会社 | 抗体−薬物コンジュゲートとキナーゼ阻害剤の組み合わせ |
CN113924317A (zh) | 2019-02-01 | 2022-01-11 | 葛兰素史克知识产权开发有限公司 | 贝兰他单抗莫福汀与派姆单抗组合用于治疗癌症 |
CA3133652A1 (en) | 2019-04-01 | 2020-10-08 | Genentech, Inc. | Compositions and methods for stabilizing protein-containing formulations |
CN112007169B (zh) * | 2019-05-30 | 2022-03-08 | 湖南大学 | 一种核酸适配体药物偶联物及其制备方法和用途 |
CN110205302B (zh) * | 2019-06-24 | 2021-03-23 | 扬州大学 | 一株分泌抗麦考酚酸单克隆抗体的细胞株、其单克隆抗体及其应用 |
WO2020261097A1 (en) | 2019-06-26 | 2020-12-30 | Glaxosmithkline Intellectual Property Development Limited | Il1rap binding proteins |
CN110551214A (zh) * | 2019-08-27 | 2019-12-10 | 杨澜 | 一种人源化抗Periostin单克隆抗体、及其制备方法和应用 |
CN115038466A (zh) | 2020-01-28 | 2022-09-09 | 葛兰素史密斯克莱知识产权发展有限公司 | 联合治疗及其用途和方法 |
WO2021260583A1 (en) | 2020-06-24 | 2021-12-30 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and dna-pk inhibitor |
JP2023542066A (ja) | 2020-06-24 | 2023-10-05 | アストラゼネカ ユーケー リミテッド | 抗体-薬物コンジュゲートとatr阻害剤との組み合わせ |
WO2021260582A1 (en) | 2020-06-24 | 2021-12-30 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and aurora b inhibitor |
CN116194109A (zh) | 2020-06-24 | 2023-05-30 | 阿斯利康(英国)有限公司 | 抗体-药物缀合物和atm抑制剂的组合 |
JP2023542065A (ja) | 2020-06-24 | 2023-10-05 | アストラゼネカ ユーケー リミテッド | 抗体-薬物複合物及びcdk9阻害剤の組み合わせ |
IL300030A (en) | 2020-07-20 | 2023-03-01 | Daiichi Sankyo Co Ltd | Combination of an anti-2HER drug-antibody conjugate with a dimerization suppressor |
IL301921A (en) | 2020-10-09 | 2023-06-01 | Daiichi Sankyo Co Ltd | Combining an antibody-drug conjugate and a selective 1PARP inhibitor |
KR20230106645A (ko) | 2020-11-11 | 2023-07-13 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 콘주게이트와 항 SIRPα 항체의 조합 |
TW202334238A (zh) | 2021-11-30 | 2023-09-01 | 日商第一三共股份有限公司 | 蛋白酶分解性遮蔽抗體 |
TW202333800A (zh) | 2021-12-28 | 2023-09-01 | 英商阿斯特捷利康英國股份有限公司 | 抗體-藥物結合物及rasg12c抑制劑之組合 |
WO2023209591A1 (en) | 2022-04-27 | 2023-11-02 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor |
TW202400650A (zh) | 2022-05-11 | 2024-01-01 | 日商第一三共股份有限公司 | 抗體與cd47抑制劑之組合 |
TW202412859A (zh) | 2022-07-28 | 2024-04-01 | 英商阿斯特捷利康英國股份有限公司 | 抗體-藥物結合物及雙特異性檢查點抑制劑之組合 |
CN117224689B (zh) * | 2023-11-16 | 2024-02-23 | 上海复宏汉霖生物技术股份有限公司 | 联合抗her2抗体和化疗剂治疗胃癌的用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989006692A1 (en) * | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
WO1998017797A1 (en) * | 1996-10-18 | 1998-04-30 | Genentech, Inc. | ANTI-ErbB2 ANTIBODIES |
WO1999031140A1 (en) * | 1997-12-12 | 1999-06-24 | Genentech, Inc. | TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
Family Cites Families (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
DE3587657D1 (de) | 1984-01-30 | 1993-12-23 | Imp Cancer Res Tech | Verbesserungen an wachstumsfaktoren. |
US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
US5401638A (en) | 1986-06-04 | 1995-03-28 | Oncogene Science, Inc. | Detection and quantification of neu related proteins in the biological fluids of humans |
US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
US4968603A (en) | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
US5824311A (en) | 1987-11-30 | 1998-10-20 | Trustees Of The University Of Pennsylvania | Treatment of tumors with monoclonal antibodies against oncogene antigens |
US5720937A (en) * | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
AU632065B2 (en) | 1988-09-23 | 1992-12-17 | Novartis Vaccines And Diagnostics, Inc. | Cell culture medium for enhanced cell growth, culture longevity and product expression |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
ES2106033T3 (es) | 1989-05-19 | 1997-11-01 | Genentech Inc | Dominio extracelular de her2. |
EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
EP0739904A1 (en) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
WO1991003489A1 (en) | 1989-09-08 | 1991-03-21 | The Johns Hopkins University | Structural alterations of the egf receptor gene in human gliomas |
DE68926248T2 (de) | 1989-09-29 | 1996-12-19 | Oncogene Science Inc | p100 "neu" menschlisches Protein and Verwendung dieses Proteins zum Nachweis von preneoplasmatischen- oder neoplasmatischen beim Menschen |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
CA2026147C (en) * | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
EP0586505A1 (en) | 1991-05-14 | 1994-03-16 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
IL101943A0 (en) | 1991-05-24 | 1992-12-30 | Genentech Inc | Structure,production and use of heregulin |
CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
US5264586A (en) | 1991-07-17 | 1993-11-23 | The Scripps Research Institute | Analogs of calicheamicin gamma1I, method of making and using the same |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
DK1136556T3 (da) | 1991-11-25 | 2005-10-03 | Enzon Inc | Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner |
CA2129663C (en) | 1992-02-06 | 2005-07-05 | James S. Huston | Biosynthetic binding protein for cancer marker |
ATE244763T1 (de) | 1992-02-11 | 2003-07-15 | Cell Genesys Inc | Erzielen von homozygotem durch zielgerichtete genetische ereignisse |
US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
WO1993021319A1 (en) | 1992-04-08 | 1993-10-28 | Cetus Oncology Corporation | HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
IL105914A0 (en) | 1992-06-04 | 1993-10-20 | Univ California | Methods and compositions for in vivo gene therapy |
AU687346B2 (en) | 1992-06-30 | 1998-02-26 | Oncologix, Inc. | A combination of anti-erbB-2 monoclonal antibodies and method of using |
ATE149570T1 (de) | 1992-08-17 | 1997-03-15 | Genentech Inc | Bispezifische immunoadhesine |
FR2697752B1 (fr) * | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Compositions antitumorales contenant des dérivés du taxane. |
NZ258392A (en) | 1992-11-13 | 1997-09-22 | Idec Pharma Corp | Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona |
CA2103323A1 (en) | 1992-11-24 | 1994-05-25 | Gregory D. Plowman | Her4 human receptor tyrosine kinase |
ATE186219T1 (de) | 1993-03-24 | 1999-11-15 | Berlex Biosciences | Kombination von antihormonale und bindende moleküle zur krebsbehandlung |
AU6527894A (en) | 1993-03-30 | 1994-10-24 | Trustees Of The University Of Pennsylvania, The | Prevention of tumors with monoclonal antibodies against (neu) |
JPH09506250A (ja) | 1993-11-23 | 1997-06-24 | ジェネンテク,インコーポレイテッド | Rseと命名される蛋白チロシンキナーゼ |
ATE207366T1 (de) | 1993-12-24 | 2001-11-15 | Merck Patent Gmbh | Immunokonjugate |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
US5910486A (en) | 1994-09-06 | 1999-06-08 | Uab Research Foundation | Methods for modulating protein function in cells using, intracellular antibody homologues |
US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
EP1241264A1 (en) | 1994-12-02 | 2002-09-18 | Chiron Corporation | Monoclonal antibodies to colon cancer antigen |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
EP0831880A4 (en) | 1995-06-07 | 2004-12-01 | Imclone Systems Inc | ANTIBODIES AND FRAGMENTS OF ANTIBODIES INHIBITING TUMOR GROWTH |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
US5837234A (en) | 1995-06-07 | 1998-11-17 | Cytotherapeutics, Inc. | Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane |
CA2245835A1 (en) | 1995-06-14 | 1997-01-03 | The Regents Of The University Of California | Novel high affinity human antibodies to tumor antigens |
PT1516628E (pt) | 1995-07-27 | 2013-09-24 | Genentech Inc | Formulação de proteína liofilizada isotónica estável |
US5783186A (en) | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
DE69732711T2 (de) * | 1996-07-12 | 2006-03-16 | Genentech, Inc., South San Francisco | Gamma-heregulin |
DK0918746T3 (da) * | 1996-08-12 | 2003-08-04 | Celgene Corp | Immunterapeutiske midler og deres anvendelse til reduktion af cytokinniveauer |
US5994071A (en) | 1997-04-04 | 1999-11-30 | Albany Medical College | Assessment of prostate cancer |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
AU9805398A (en) | 1997-10-15 | 1999-05-03 | Children's Medical Center Corporation | Novel human egf receptors and use thereof |
US6316462B1 (en) * | 1999-04-09 | 2001-11-13 | Schering Corporation | Methods of inducing cancer cell death and tumor regression |
ES2320311T3 (es) * | 1999-05-14 | 2009-05-21 | Genentech, Inc. | Tratamiento con anticuerpos anti-erbb2. |
BR0012195A (pt) * | 1999-06-25 | 2002-07-23 | Genentech Inc | Método para tratar câncer de próstata num ser humano, artigo de fabricação e uso de um anticorpo que liga erbb2 |
SI1189641T1 (sl) * | 1999-06-25 | 2009-12-31 | Genentech Inc | Humanizirana protitelesa proti ErbB2 in zdravljenje s protitelesi proti ErbB2 |
MXPA01013240A (es) * | 1999-06-25 | 2002-06-21 | Genentech Inc | Metodo de tratamiento utilizando conjugados de anticuerpo contra erbb-maytansionoide. |
US6627196B1 (en) * | 1999-08-27 | 2003-09-30 | Genentech, Inc. | Dosages for treatment with anti-ErbB2 antibodies |
-
2000
- 2000-06-23 SI SI200031040T patent/SI1189641T1/sl unknown
- 2000-06-23 AT AT00943115T patent/ATE437655T1/de active
- 2000-06-23 IL IL14695400A patent/IL146954A0/xx unknown
- 2000-06-23 CZ CZ20014596A patent/CZ299702B6/cs unknown
- 2000-06-23 NZ NZ531426A patent/NZ531426A/en not_active IP Right Cessation
- 2000-06-23 TR TR2001/03756T patent/TR200103756T2/xx unknown
- 2000-06-23 CN CNA2007101411114A patent/CN101121750A/zh active Pending
- 2000-06-23 SI SI200031080T patent/SI2283867T1/sl unknown
- 2000-06-23 CN CNB008118981A patent/CN100340575C/zh not_active Expired - Lifetime
- 2000-06-23 CA CA2727172A patent/CA2727172A1/en not_active Abandoned
- 2000-06-23 NZ NZ516830A patent/NZ516830A/en not_active IP Right Cessation
- 2000-06-23 RU RU2002100905/15A patent/RU2270029C2/ru active Protection Beyond IP Right Term
- 2000-06-23 KR KR1020077020771A patent/KR100797308B1/ko active IP Right Review Request
- 2000-06-23 AR ARP000103157A patent/AR024464A1/es active IP Right Grant
- 2000-06-23 GB GB0200506A patent/GB2368796B/en not_active Expired - Lifetime
- 2000-06-23 JP JP2001505952A patent/JP4283474B2/ja not_active Expired - Lifetime
- 2000-06-23 CN CN200910126199.1A patent/CN101518653B/zh not_active Expired - Lifetime
- 2000-06-23 SI SI200031088T patent/SI2283866T1/sl unknown
- 2000-06-23 BR BRPI0012198A patent/BRPI0012198B8/pt not_active IP Right Cessation
- 2000-06-23 WO PCT/US2000/017366 patent/WO2001000245A2/en active IP Right Grant
- 2000-06-23 PL PL384502A patent/PL203326B1/pl unknown
- 2000-06-23 PL PL352321A patent/PL204629B1/pl unknown
- 2000-06-23 HU HU0201695A patent/HU226742B1/hu active Protection Beyond IP Right Term
- 2000-06-23 ES ES00943115T patent/ES2329437T3/es not_active Expired - Lifetime
- 2000-06-23 AT AT0911000A patent/AT500848B1/de not_active IP Right Cessation
- 2000-06-23 DE DE60042648T patent/DE60042648D1/de not_active Expired - Lifetime
- 2000-06-23 EP EP00943115A patent/EP1189641B1/en not_active Expired - Lifetime
- 2000-06-23 AU AU57632/00A patent/AU784045B2/en active Active
- 2000-06-23 BR BR122014028365A patent/BR122014028365B8/pt active IP Right Grant
- 2000-06-23 EP EP09007811A patent/EP2112167A3/en not_active Withdrawn
- 2000-06-23 PT PT00943115T patent/PT1189641E/pt unknown
- 2000-06-23 GE GEAP200011523A patent/GEP20104998B/en unknown
- 2000-06-23 KR KR1020017016490A patent/KR100850389B1/ko active Protection Beyond IP Right Term
- 2000-06-23 CH CH02367/01A patent/CH694589A5/de not_active IP Right Cessation
- 2000-06-23 DK DK00943115.6T patent/DK1189641T5/da active
- 2000-06-23 DE DE10084743T patent/DE10084743T1/de not_active Withdrawn
- 2000-06-23 CA CA002376596A patent/CA2376596C/en not_active Expired - Lifetime
- 2000-06-23 MX MXPA01013458A patent/MXPA01013458A/es active IP Right Grant
- 2000-06-23 CN CN2007101411129A patent/CN101121021B/zh not_active Expired - Lifetime
-
2001
- 2001-11-28 ZA ZA200109786A patent/ZA200109786B/en unknown
- 2001-12-06 IL IL146954A patent/IL146954A/en active Protection Beyond IP Right Term
- 2001-12-13 ZA ZA200110263A patent/ZA200110263B/xx unknown
- 2001-12-21 NO NO20016329A patent/NO328377B1/no not_active IP Right Cessation
-
2002
- 2002-08-08 HK HK02105805.2A patent/HK1044888A1/xx not_active IP Right Cessation
-
2005
- 2005-10-25 RU RU2005132788/15A patent/RU2430739C9/ru active
- 2005-12-07 AU AU2005242195A patent/AU2005242195B2/en not_active Expired
-
2008
- 2008-12-26 JP JP2008333670A patent/JP2009142280A/ja not_active Withdrawn
-
2009
- 2009-03-03 IL IL197359A patent/IL197359A0/en unknown
- 2009-05-05 NO NO20091792A patent/NO336040B1/no not_active IP Right Cessation
- 2009-10-20 CY CY20091101084T patent/CY1109525T1/el unknown
-
2013
- 2013-03-07 LU LU92164C patent/LU92164I2/fr unknown
- 2013-03-08 FR FR13C0016C patent/FR13C0016I2/fr active Active
- 2013-03-08 BE BE2013C020C patent/BE2013C020I2/fr unknown
- 2013-03-11 CY CY2013010C patent/CY2013010I1/el unknown
- 2013-03-12 NO NO2013005C patent/NO2013005I1/no not_active IP Right Cessation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989006692A1 (en) * | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
US5677171A (en) * | 1988-01-12 | 1997-10-14 | Genentech, Inc. | Monoclonal antibodies directed to the HER2 receptor |
WO1998017797A1 (en) * | 1996-10-18 | 1998-04-30 | Genentech, Inc. | ANTI-ErbB2 ANTIBODIES |
WO1999031140A1 (en) * | 1997-12-12 | 1999-06-24 | Genentech, Inc. | TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100340575C (zh) | 人源化抗ErbB2抗体及其在制备药物中的应用 | |
CN1379684A (zh) | 使用抗-ErbB2抗体治疗前列腺癌 | |
CN1269839C (zh) | 用于治疗的抗ErbB2抗体 | |
CN100482281C (zh) | 抗ErbB抗体-类美坦素偶联物在制备药物中的应用 | |
US7097840B2 (en) | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates | |
CN1382060A (zh) | 用于抗ErbB2抗体治疗的制剂 | |
JP5069843B2 (ja) | 抗ErbB2抗体を用いる処置に応答性である腫瘍を同定するための方法 | |
CN1464908A (zh) | 多价抗体及其应用 | |
CN1234072A (zh) | 抗ErbB2抗体 | |
JP2003503365A5 (US07585860-20090908-C00154.png) | ||
CN101044164A (zh) | 血管生成素样4蛋白抑制剂,组合,以及其用途 | |
CN1993146A (zh) | 抗体-药物偶联物和方法 | |
CN1835768A (zh) | 鉴定对用抗ErbB2抗体处理响应的肿瘤的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CX01 | Expiry of patent term |
Granted publication date: 20071003 |
|
CX01 | Expiry of patent term |